EUVIMEDEUVIMED entdecken
Crossref

In patients with follicular lymphoma, delayed-onset neutropenia induced by anti-CD20 monoclonal antibodies frequently occurs during maintenance therapy and is preferentially associated with obinutuzumab

Nashwa Fadaos, Yossi Ben Dor, Tehila Azoulay, Ronit Leiba, Nurit Sharon-Horesh, Tsofia Levi, Netanel A Horowitz, Inna Tzoran, Noa Lavi, Ofrat Beyar-Katz, Eldad J Dann, Tsila Zuckerman und 1 weitere

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-06130-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Nashwa Fadaos und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Neutropenia, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of anti-CD20 monoclonal antibody (MoAb)-associated delayed-onset neutropenia (DON) varies between 8 and 27%. Despite the wide use of MoAbs as maintenance in follicular lymphoma (FL), data regarding DON occurrence and clinical consequences are limited. This study assessed DON prevalence, severity and risk factors in FL patients during maintenance. Data were retrieved from electronic medical records of FL patients treated at Rambam between 2006 and 2021. The maintenance cohort included 155 patients receiving 165 treatment courses; the non-maintenance cohort included 58 patients receiving 67 courses. Median time on maintenance was 1.81 ± 0.28 years. During maintenance, 23.2% of patients developed DON, with 13.8% experiencing at least one recurrent event. In the non-maintenance cohort, 29.3% developed DON, with 38.8% recurrence. Median time from maintenance initiation to the first neutropenic episode was 5 (1.25-12) months, whereas in the non-maintenance cohort, DON occurred earlier [1.9 (0.97-3.71) months; p = 0.06]. The only DON risk factors in patients on maintenance were induction with the obinutuzumab/bendamustine combination [odds ratio (OR): 4.546 (95%CI = 1.419-14.563); p = 0.011] or obinutuzumab maintenance [OR: 3.138 (95%CI = 1.23-7.94); p = 0.016]. In the non-maintenance cohort, such factors included ≥ 1 line of therapy [OR: 3.93 (95%CI = 1.00-15.38); p = 0.04] and a lower absolute neutrophil count at induction completion. Differences in the likelihood of DON development between patients receiving maintenance with obinutuzumab or rituximab possibly reflect mechanistic dissimilarities between type I and type II MoAbs. Regardless, prolonged MoAb use bears a mitigatory effect, reducing recurrence of DON. The findings obtained could assist in predicting the risk of DON in individual FL patients, optimizing informed treatment choices.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularNeutropeniaAntibodies, Monoclonal, HumanizedHumansMaleFemaleMiddle AgedAgedAdultAntigens, CD20Risk FactorsMaintenance ChemotherapyRituximabRetrospective StudiesAged, 80 and overAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

Anti-CD20 monoclonal antibodiesDelayed-onset neutropeniaFollicular lymphomaMaintenance therapyObinutuzumab

Substanzen

obinutuzumabAntibodies, Monoclonal, HumanizedAntigens, CD20RituximabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
  • Hematology Laboratory, Rambam Health Care Campus, Haifa, Israel.
  • Department of Statistics, Rambam Health Care Campus, Haifa, Israel.
  • Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, 8, Ha'Aliya Street, Haifa, 3109601, Israel.
  • The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. s_ringelstein@rambam.health.gov.il.
  • Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, 8, Ha'Aliya Street, Haifa, 3109601, Israel. s_ringelstein@rambam.health.gov.il.

Zitieren

APA

Fadaos, N., Dor, Y. B., Azoulay, T., Leiba, R., Sharon-Horesh, N., Levi, T., Horowitz, N. A., Tzoran, I., Lavi, N., Beyar-Katz, O., Dann, E. J., Zuckerman, T., & Ringelstein-Harlev, S. (2024). In patients with follicular lymphoma, delayed-onset neutropenia induced by anti-CD20 monoclonal antibodies frequently occurs during maintenance therapy and is preferentially associated with obinutuzumab. Annals of Hematology. https://doi.org/10.1007/s00277-024-06130-y

Vancouver

Fadaos N, Dor YB, Azoulay T, Leiba R, Sharon-Horesh N, Levi T, et al. In patients with follicular lymphoma, delayed-onset neutropenia induced by anti-CD20 monoclonal antibodies frequently occurs during maintenance therapy and is preferentially associated with obinutuzumab. Annals of Hematology. 2024. doi:10.1007/s00277-024-06130-y

BibTeX
@article{Fadaos2024,
  author = {Fadaos, Nashwa and Dor, Yossi Ben and Azoulay, Tehila and Leiba, Ronit and Sharon-Horesh, Nurit and Levi, Tsofia and Horowitz, Netanel A and Tzoran, Inna and Lavi, Noa and Beyar-Katz, Ofrat and Dann, Eldad J and Zuckerman, Tsila and Ringelstein-Harlev, Shimrit},
  title = {In patients with follicular lymphoma, delayed-onset neutropenia induced by anti-CD20 monoclonal antibodies frequently occurs during maintenance therapy and is preferentially associated with obinutuzumab},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-06130-y}
}
Kostenlos starten →